EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children

Safaa Bazbaz, Irina Zaidman, Ehud Even-Or iD, Polina Stepensky, Razan Sakran, Daniel Kurnik iD, Gefen Aldouby-Bier

Pharmaceutics · 21.08.2025 · 17 (8) · 1081

DOI: 10.3390/pharmaceutics17081081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 21.08.2025. Verfasst von Safaa Bazbaz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.Box 12272, Jerusalem 9112102, Israel. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Busulfan is a key component of myeloablative conditioning regimens in hematopoietic stem cell transplantation (HSCT) for pediatric patients with acute myeloid leukemia, solid tumors, and certain non-malignant diseases. This study compares the clinical outcomes of once-daily (BU1) versus four-times-daily (BU4) busulfan dosing regimens in pediatric HSCT recipients.

Methods

A retrospective analysis was conducted on 70 pediatric patients who underwent HSCT at Hadassah Medical Center between June 2018 and October 2023. Thirty-five patients received the BU4 regimen, and 35 received BU1. The primary endpoint was 100-day event-free survival (EFS).

Results

There was no statistically significant difference in 100-day event-free survival between the BU1 group (88.6%) and the BU4 group (85.7%; p = 0.768). Similarly, no significant differences were found in time to neutrophil engraftment (p = 0.251) or platelet engraftment (p = 0.688). Sinusoidal obstruction syndrome (SOS) occurred in 17.1% of patients in each group. No significant differences were observed in the increase in liver enzyme levels (p = 1.0). The incidence of acute graft-versus-host disease was comparable between the groups (41.9% for BU1 vs. 40.0% for BU4; p = 0.878).

Conclusions

Once-daily and four-times-daily busulfan regimens demonstrated comparable clinical outcomes in terms of efficacy and adverse events. Further prospective studies are needed to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

busulfanconditioning therapyhematopoietic stem cell transplantationmodel-informed precision dosingpediatricspharmacokineticssinusoidal obstruction syndrometherapeutic drug monitoring

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, P.O.Box 12272, Jerusalem 9112102, Israel.
  • Hadassah Medical Center, Faculty of Medicine, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, P.O.Box 12000, Jerusalem 91120, Israel.
  • Clinical Pharmacology and Toxicology Section, Rambam Health Care Campus, P.O.Box 9602, Haifa 3109601, Israel.
  • Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3200003, Israel.

ORCID-Profile: Ehud Even-Or, Daniel Kurnik

Zitieren

APA

Bazbaz, S., Zaidman, I., Even-Or, E., Stepensky, P., Sakran, R., Kurnik, D., & Aldouby-Bier, G. (2025). Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children. Pharmaceutics, 17(8), 1081. https://doi.org/10.3390/pharmaceutics17081081

Vancouver

Bazbaz S, Zaidman I, Even-Or E, Stepensky P, Sakran R, Kurnik D, et al. Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children. Pharmaceutics. 2025;17(8):1081. doi:10.3390/pharmaceutics17081081

BibTeX
@article{Bazbaz2025,
  author = {Bazbaz, Safaa and Zaidman, Irina and Even-Or, Ehud and Stepensky, Polina and Sakran, Razan and Kurnik, Daniel and Aldouby-Bier, Gefen},
  title = {Once-Daily Versus Four-Times-Daily Intravenous Busulfan with Therapeutic Drug Monitoring as Conditioning for Hematopoietic Cell Transplantation in Children},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {8},
  pages = {1081},
  doi = {10.3390/pharmaceutics17081081}
}
Kostenlos starten →